Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]

Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy

Dr Theodore Johnson - Georgia Cancer Center, Augusta, USA

Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy ( Dr Theodore Johnson - Georgia Cancer Center, Augusta, USA )

Impact of microbiome on head and neck cancers

Dr Young Jun Kim - Vanderbilt-Ingram Cancer Center, Nashville, USA

Impact of microbiome on head and neck cancers ( Dr Young Jun Kim - Vanderbilt-Ingram Cancer Center, Nashville, USA )

First-in-human trial results of RET targeted BLU-667

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

First-in-human trial results of RET targeted BLU-667 ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

Treating RET alterations with novel therapy BLU-667

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

Treating RET alterations with novel therapy BLU-667 ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

AKT inhibitors in research and application

Dr Brian Schwartz - ArQule, Burlington, USA

AKT inhibitors in research and application ( Dr Brian Schwartz - ArQule, Burlington, USA )

Reducing recurrence of advanced melanoma with pembrolizumab

Prof Alex Eggermont - Paris-Sud University, Paris, France

Reducing recurrence of advanced melanoma with pembrolizumab ( Prof Alex Eggermont - Paris-Sud University, Paris, France )

Results of KEYNOTE-054; melanoma patients treated with pembrolizumab.

Prof Alex Eggermont - Paris-Sud University, Paris, France

Results of KEYNOTE-054; melanoma patients treated with pembrolizumab. ( Prof Alex Eggermont - Paris-Sud University, Paris, France )

Management of marker negative stage II testicular cancer

Dr Christian Kollmannsberger - University of British Columbia, Vancouver, Canada

Management of marker negative stage II testicular cancer ( Dr Christian Kollmannsberger - University of British Columbia, Vancouver, Canada )

Editor's Choice for February 2018

Prof Gordon McVie - Founding Editor, ecancer

Editor's Choice for February 2018 ( Prof Gordon McVie - Founding Editor, ecancer )

The EMA perspective on drug approval process in the era of precision medicine

Jorge Camarero - Spanish Agency of Medicines and Medical Services, Spain

The EMA perspective on drug approval process in the era of precision medicine ( Jorge Camarero - Spanish Agency of Medicines and Medical Services, Spain )

Expert insight: Metastatic hormone sensitive prostate cancer latest

Professor Karim Fizazi and Professor Nicholas James

Expert insight: Metastatic hormone sensitive prostate cancer latest ( Professor Karim Fizazi and Professor Nicholas James )

Comment: Urothelial cancer research from ASCO GU 2018

Dr Guru Sonpavde - Dana-Farber Cancer Institute, Boston, USA

Comment: Urothelial cancer research from ASCO GU 2018 ( Dr Guru Sonpavde - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer